Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Terlipressin vs Midodrine and Octreotide for Hepatorenal Syndrome
NCT00742339Phase 3Terminated
- Sponsor
- Università di Padova
- Start
- May 2005
- Primary completion
- Oct 2013
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of midodrine and Octreotide long-acting injection in hepatorenal syndrome (HRS), sponsored by Università di Padova. Primary endpoint: Complete reform of the renal function at 15 days. Started May 2005; status: terminated.
02
Drugs
midodrineOctreotide long-acting injection
03
Conditions
hepatorenal syndrome (HRS)
Beyond the preview
Go deeper on NCT00742339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00742339.